Copyright
©2012 Baishideng Publishing Group Co.
World J Clin Oncol. Mar 10, 2012; 3(3): 32-42
Published online Mar 10, 2012. doi: 10.5306/wjco.v3.i3.32
Published online Mar 10, 2012. doi: 10.5306/wjco.v3.i3.32
Targeted deregulated element | Name of inhibitory agent |
mAb against stem cell-like surface marker | |
CD133 | Anti-CD133 mAb |
ABCB5 | Anti-ABCB5 mAb |
Growth factor signaling inhibitor | |
EGFR (erbB1) antibody | mAb-C225, cetuximab (IMC-C225), IMC-1121B |
EGFR-TKI | Gefitinib, erlotinib, AG1478, PD153035 |
Anti-EGF antibody | ABX-EGF |
Pan-erbB1/erbB2/erbB3/erbB4-TKI | Cl1033 |
MET | SUI1274 |
Hedgehog | Anti-SHH antibody, SMO inhibitor (cyclopamine, GDC-0449, BMS-833923, NVP-LDE225, IPI-926 IPI-269609) |
Wnt/β-catenin | Anti-Wnt antibody, WIF-1 |
Notch | γ-secretase inhibitor (DAPT, MK-0752,GSI-18) |
Nodal/Cripto | LEFTY, Anti-Cripto mAb |
KIT | Imatinib mesylate, dasatinib |
HA/CD44 | Anti-CD44 mAb, soluble CD44 protein |
VEGF | Anti-VEGF antibody (bevacizumab) |
VEGFR2 | Anti-VEGFR-2 mAb (DC101) |
VEGFR2/EGFR/RET | Vandetanib (ZD6474) |
VEGFRs, PDGFRs, KIT | Sunitinib |
B-Raf, C-Raf, KIT, PDGFRs, VEGFR2 and 3 | Sorafenib |
ECM component/integrin | Anti-integrin antibody |
CXCR4 | AMD3100 |
Intracellular signaling inhibitor | |
B-RafE600V | PLX 4032, PLX4720 |
MEK1/2 | AZD6244 (ARRY-142886), PD0325901 |
PI3K | LY294002 |
mTOR | Rapamycin, CCl-779, |
PI3K/mTOR | PI-103 |
NF-κB | IkBα inhibitor, sulfasalazine, bortezomib (PS-341) salinosporamides A (NPI-0052), parthenolide |
COX-2 | NS-396, etodolax, celecoxib, rofecoxib |
Immunomodulatory agent | |
Immune and/or vascular systems | Imiquimod, INF-α, IL-2, IL-21, anti-CTLA-4, mAb (ipilimumab “MDX 010”and tremelimumab “CP-675, 206”) |
- Citation: Mimeault M, Batra SK. Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol 2012; 3(3): 32-42
- URL: https://www.wjgnet.com/2218-4333/full/v3/i3/32.htm
- DOI: https://dx.doi.org/10.5306/wjco.v3.i3.32